NEXGEL (NASDAQ:NXGL) has announced positive results from its proof-of-concept study on idiclofenac hydrogel patches designed to treat pain caused by arthritis, joint pain, muscle aches and more.
The Langhorne, Pennsylvania-based company said the study compared its diclofenac hydrogel patches with the leading commercially available topical treatment, assessing the formulations, skin retention and permeation of the products through the skin.
The results revealed NEXGEL's diclofenac hydrogel patches delivered an equivalent dose faster and are longer-acting compared to the current standard-of-care, along with showing gentle skin adhesion for eight to 12 hours, according to the company.
READ: NEXGEL develops hydrogel patch to treat lazy eye; works better for younger children
Diclofenac patches are non-steroidal anti-inflammatory drugs used to treat short-term pain due to minor strains, sprains and bruises. The early study results confirm the potential effectiveness of NEXGEL's technology in drug delivery patches, the company said.
NEXGEL CEO Adam Levy said the early-stage data shows the efficiency of the hydrogel and the potential for this product to become a preferred alternative to treat pain.
"As the company moves toward next steps of human clinical studies, we are also seeking potential strategic partners as we see this as a potential platform technology. We look forward to updating the market with our progress," Levy said in a statement.
NEXGEL is a provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications.
Contact the author at susie@proactiveinvestors.com